SCHEMBL16211302

SCHEMBL16211302

COC(=O)c1ccc(CN(C(=O)N2CCOCC2)c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.66
HDAC6 Q9UBN7 9/20 0.66
HDAC8 Q9BY41 6/20 0.66
HDAC5 Q9UQL6 4/20 0.56
GAA P10253 1/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
CASP1 P29466 1/20 0.47
HTT P42858 1/20 0.47
CASP7 P55210 1/20 0.47
MLYCD O95822 2/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
LTB4R2 Q9NPC1 1/20 0.45
ALOX15 P16050 1/20 0.45
MGLL Q99685 1/20 0.45
RORC P51449 1/20 0.45
NR1H4 Q96RI1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29879232 0.95 HDAC6 (0.60) HDAC1HDAC6HDAC8HDAC5GAA
SCHEMBL16211284 0.90 HDAC1 (0.54) HDAC1HDAC6HDAC8HDAC5HPGD
SCHEMBL16211278 0.90 HDAC1 (0.57) HDAC1HDAC6HDAC8HDAC5GAA
SCHEMBL16211327 0.90 HDAC6 (0.53) HDAC1HDAC6HDAC8HDAC5POLB
SCHEMBL16221530 0.89 HDAC6 (0.52) HDAC1HDAC6HDAC8HDAC5POLB
SCHEMBL16211581 0.89 HDAC1 (0.52) HDAC1HDAC6HDAC8HDAC5ALDH1A1
SCHEMBL23407545 0.88 HDAC1 (0.70) HDAC1HDAC6HDAC8HDAC5ALDH1A1
SCHEMBL16211664 0.88 MLYCD (0.57) HDAC1HDAC6HDAC8GAAALDH1A1
SCHEMBL16211818 0.88 HDAC1 (0.52) HDAC1HDAC6HDAC8HDAC5ALDH1A1
SCHEMBL22218368 0.88 HDAC1 (0.51) HDAC1HDAC6HDAC8HDAC5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-10 US disclosed
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-10 US disclosed
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-10 US disclosed
WO-2023073600-A1 COMPOSITIONS FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS (IPF) CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-05-04 WO disclosed
US-11571426-B2 Compositions for preventing or treating lupus CHONG KUN DANG PHARMACEUTICAL CORP. 2023-02-07 US disclosed
US-11571426-B2 Compositions for preventing or treating lupus CHONG KUN DANG PHARMACEUTICAL CORP. 2023-02-07 US disclosed
WO-2022203429-A1 COMPOSITION FOR PREVENTING OR TREATING MULTIPLE SCLEROSIS CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2022-09-29 WO disclosed
US-20220296599-A1 Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2022-09-22 US disclosed
CN-114599367-A Composition for preventing or treating Chronic Obstructive Pulmonary Disease (COPD) 株式会社钟根堂 2022-06-07 CN disclosed
EP-3331864-B1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2021-11-03 EP disclosed
WO-2019103524-A1 COMPOSITIONS FOR PREVENTING OR TREATING LUPUS CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2019-05-31 WO disclosed
US-9878986-B2 Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-01-30 US disclosed
US-9878986-B2 Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-01-30 US disclosed
US-20170152230-A9 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-06-01 US disclosed
US-20170152230-A9 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-06-01 US disclosed
US-20160083354-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2016-03-24 US disclosed
US-20160083354-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2016-03-24 US disclosed
EP-2991982-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2016-03-09 EP disclosed
WO-2014178606-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2014-11-06 WO disclosed
WO-2014178606-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220296599-A1 Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate HDAC1, HDAC5, HDAC6 HDAC1 1/4885HDAC6 3/4885HDAC8 11/4885
US-20230248735-A1 COMPOSITIONS FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) NR1H2, CFTR, CYP11B2 HDAC1 1635/4885HDAC6 997/4885HDAC8 2983/4885
US-11571426-B2 Compositions for preventing or treating lupus SSB, TLR9, TLR5 HDAC1 96/4885HDAC6 203/4885HDAC8 444/4885
US-20160083354-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC5, HDAC4 HDAC1 1/4885HDAC6 5/4885HDAC8 10/4885
US-20170152230-A9 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC5, HDAC4 HDAC1 1/4885HDAC6 5/4885HDAC8 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.